Maribavir vs. Valganciclovir for CMV Prophylaxis in High-Risk Kidney Transplant Recipients

Summary

The purpose of this study is to find out if there is a difference in how well the standard MUSC cytomegalovirus (CMV) prevention medicine works, compared to a different medicine, in preventing CMV infections in kidney transplant recipients who are at risk for this type of infection, while also assessing the tolerability of these two regimens. The two medication regimens being compared are Valganciclovir (FDA approved to prevent and treat CMV infection) vs Maribavir (FDA approved to treat CMV infection) plus Acyclovir (FDA approved to prevent HSV infection).

Timeline

Start

2023-11-06

Primary completion

2025-06-30

Completion

2025-08-30

Publications

• Culpepper H, Overstreet M, Soliman K, Casey M, Rice T, Lively K, Scalea J, McGillicuddy J, Patel N, Taber D. A Randomized Controlled Trial Comparing the Tolerability and Efficacy of Maribavir vs. Valganciclovir for Cytomegalovirus (CMV) Prophylaxis in High-Risk Kidney Transplant Recipients: Study Protocol. Cureus. 2025 Aug 27;17(8):e91110. doi: 10.7759/cureus.91110. eCollection 2025 Aug.

Drugs

Indications